BUSINESS / MARKETS / POLITICS18 November 2026
← Story archive

Business

Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

CNBC

The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.

Read original reporting ↗

Follow the evidence

Read the original report, then compare company disclosures and the relevant official data. A headline alone does not establish an effect on markets.

Coverage timeline

Published reporting in time order

No additional matched coverage has been archived for this story yet.

This page preserves an attributed headline and brief excerpt. The publisher maintains the original report and any subsequent corrections. Report a classification or link issue →